Enhanced TRAIL sensitivity by E1A expression in human cancer and normal cell lines: Inhibition by adenovirus E1B19K and E3 proteins

Biochemical and Biophysical Research Communications

Volumn 325, Issue 4, 2004, Pages 1153-1162

  Hu, Baoli ^a   Zhu, Huabin ^a   Qiu, Songbo ^a   Su, Yue ^a   Ling, Weifang ^a   Xiao, Wei ^a   Qi, Yipeng ^a  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Adenovirus; Apoptosis; Cancer therapy; E1A; TRAIL

Indexed keywords

E1A PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADENOVIRUS 5; ARTICLE; CANCER THERAPY; CELL STRAIN HEPG2; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HELA CELL; HUMAN; HUMAN CELL; LUNG FIBROBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL LINE; VIRUS INFECTION; VIRUS MUTATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOVIRUS E1A PROTEINS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FIBROBLASTS; GENE THERAPY; HELA CELLS; HUMANS; MEMBRANE GLYCOPROTEINS; RECOMBINANT FUSION PROTEINS; REFERENCE VALUES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA; VIRAL PROTEINS;

ADENOVIRIDAE; HUMAN ADENOVIRUS TYPE 5;

EID: 8844280122     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.10.154     Document Type: Article

References (49)

1. K. Schulze-Osthoff, D. Ferrari, M. Los, S. Wesselborg, and M.E. Peter Apoptosis signaling by death receptors Eur. J. Biochem. 254 1998 439 459
2. A. Ashkenazi, and V.M. Dixit Death receptors: signaling and modulation Science 281 1998 1305 1308
3. H. Walczak, R.E. Miller, K. Ariail, B. Gliniak, T.S. Griffith, M. Kubin, W. Chin, J. Jones, A. Woodward, T. Le, C. Smith, P. Smolak, R.G. Goodwin, C.T. Rauch, J.C. Schuh, and D.H. Lynch Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo Nat. Med. 5 1999 157 163
4. S. Wang, and W.S. El-Deiry TRAIL and apoptosis induction by TNF-family death receptors Oncogene 24 2003 8628 8633
5. M.M. Keane, S.A. Ettenberg, M.M. Nau, E.K. Russell, and S. Lipkowitz Chemotherapy augments TRAIL-induced apoptosis in breast cell lines Cancer Res. 59 1999 734 741
6. K. Kim, M.J. Fisher, S.Q. Xu, and W.S. El-Deiry Molecular determinants of response to TRAIL in killing of normal and cancer cells Clin. Cancer Res. 6 2000 335 346
7. X.D. Zhang, A. Franco, K. Myers, C. Gray, T. Nguyen, and P. Hersey Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma Cancer Res. 59 1999 2747 2753
8. S. Frank, U. Kohler, G. Schackert, and H.K. Schackert Expression of TRAIL and its receptors in human brain tumors Biochem. Biophys. Res. Commun. 257 1999 454 459
9. T.S. Griffth, W.A. Chin, G.C. Jackson, D.H. Lynch, and M.Z. Kubin Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells J. Immunol. 161 1998 2833 2840
10. J.M. Routes, and J.L. Cook E1A gene expression induces susceptibility to killing by NK cells following immortalization but not adenovirus infection of human cells Virology 210 1995 421 428
11. J.L. Cook, B.A. Routes, T.A. Walker, K.L. Colvin, and J.M. Routes E1A oncogene induction of cellular susceptibility to killing by cytolytic lymphocytes through target cell sensitization to apoptotic injury Exp. Cell Res. 251 1999 414 423
12. J.L. Cook, D.L. May, A.J. Lewis, and T.A. Walker Adenovirus E1A gene induction of susceptibility to lysis by natural killer cells and activated macrophages in infected rodent cells J. Virol. 61 1987 3510 3520
13. D. Yu, and M.C. Hung The erbB2 gene as a cancer therapeutic target and the tumor-and metastasis-suppressing function of E1A Cancer Metastasis Rev. 17 1998 195 202
14. J.Y. Chang, W. Xia, R. Shao, F. Sorgi, G. Hortobagyi, L. Huang, and M.C. Hung The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer Oncogene 14 1997 561 568
15. R. Shao, D. Karunagaran, B.P. Zhou, K. Li, S.S. Lo, J. Deng, P. Chiao, and M.C. Hung Inhibition of nuclear factor-kappaB activity is involved in E1A-mediated sensitization of radiation-induced apoptosis J. Biol. Chem. 272 1997 32739 32742
16. J. Shisler, P. Duerksen-Hughes, T.M. Hemiston, W.S. Wold, and L.R. Gooding Induction of susceptibility to tumor necrosis factor by E1A is dependent on binding to either p300 or p105-Rb and induction of DNA synthesis J. Virol. 70 1996 68 77
17. J.L. Cook, T.A. Potter, D. Bellgrau, and B.A. Routes E1A oncogene expression in target cells induces cytolytic susceptibility at a post-recognition stage in the interaction with killer lymphocytes Oncogene 12 1996 833 842
18. P. Duerksen-Hughes, W.S. Wold, and L.R. Gooding Adenovirus E1A renders infected cells sensitive to cytolysis by tumor necrosis factor J. Immunol. 143 1989 4193 4200
19. J. Routes, S. Ryan, A. Clase, T. Miura, A. Kuhl, T. Potter, and J. Cook Adenovirus E1A oncogene expression in tumor cells enhances killing by TNF-related apoptosis-inducing ligand (TRAIL) J. Immunol. 165 2000 4522 4527
20. T.C. He, S. Zhou, L.T. Da Costa, J. Yu, K.W. Kinzler, and B. Vogelstein A simplified system for generating recombinant adenoviruses Proc. Natl. Acad. Sci. USA 95 1998 2509 2514
21. B.L. Hu, M.N. Joshua, C.Y. Dong, and Y.P. Qi Development of a novel recombinant adenovirus containing gfp-zeocin fusion expression cassette for conditional replication in p53-deficient human tumor cells J. Virol. Methods 117 2004 129 136
22. D.L. Spector, R.D. Goldman, and L.A. Leinwand Cells A Laboratory Manual 1998 Cold Spring Harbor Laboratory Cold Spring Harbor, NY
23. T. Yamanaka, K. Shiraki, K. Sugimoto, T. Ito, K. Fujikawa, M. Ito, K. Takase, M. Moriyama, T. Nakano, and A. Suzuki Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines Hepatology 32 2000 482 490
24. T.S. Griffith, R.D. Anderson, B.L. Davidson, R.D. Williams, and T.L. Ratliff Adenoviral-mediated transfer of the TRAIL/Apo-2 ligand gene induces tumor cell apoptosis J. Immunol. 165 2000 2886 2894
25. Z. Darzynkiewicz, X. Li, and J. Gong Assays of cell viability: discrimination of cells dying by apoptosis Z. Darzynkiewicz H.A. Crissman J.R. Robinson Methods in Cell Biology: Flow cytometry second ed. 1994 Academic Press New York
26. S.R. Wiley, K. Schooley, P.J. Smolak, W.S. Din, C.P. Huang, J.K. Nicholl, G.R. Sutherland, T.D. Smith, C. Rauch, and C.A. Smith Identification and characterization of a new member of the TNF family that induces apoptosis Immunity 3 1995 673 682
27. P.H. Gallimore, and A.S. Turnell Adenovirus E1A: remodelling the host cell, a life or death experience Oncogene 20 2001 7824 7835
28. J.S. Mymryk Tumour suppressive properties of the adenovirus 5 E1A oncogene Oncogene 13 1996 1581 1599
29. S. Kreuz, D. Siegmund, P. Scheurich, and H. Wajant NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling Mol. Cell. Biol. 21 2001 3964 3973
30. O. Micheau, S. Lens, O. Gaide, K. Alevizopoulos, and J. Tschopp NF-kappaB signals induce the expression of c-FLIP Mol. Cell. Biol. 21 2001 5299 5305
31. F. Su, and R.J. Schneider Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis factor alpha Proc. Natl. Acad. Sci. USA 94 1997 8744 8749
32. L.R. Gooding, L. Aquino, P.J. Duerksen-Hughes, D. Day, T.M. Horton, S. Yei, and S.M. Wold The E1B 19,000-molecular-weight protein of group C adenoviruses prevents tumor necrosis factor cytolysis of human cells but not of mouse cells J. Virol. 65 1991 3083 3094
33. L. Gooding, T. Ranheim, A. Tollefson, L. Aquino, P. Duerksen-Hughes, T. Horton, and W.S. Wold The 10,400- and 14,500-dalton proteins encoded by region E3 of adenovirus function together to protect many but not all mouse cell lines against lysis by tumor necrosis factor J. Virol. 65 1991 4114 4123
34. A.E. Tollefson, K. Toth, K. Doronin, M. Kuppuswamy, O.A. Doronina, D.L. Lichtenstein, T.W. Hermiston, C.A. Smith, and W.S. Wold Inhibition of TRAIL-induced apoptosis and forced internalization of TRAIL receptor 1 by adenovirus proteins J. Virol. 75 2001 8875 8887
35. C.A. Benedict, P.S. Norris, T.I. Prigozy, J.L. Bodmer, J.A. Mahr, C.T. Garnett, F. Martinon, J. Tschopp, L.R. Gooding, and C.F. Ware Three adenovirus E3 proteins cooperate to evade apoptosis by tumor necrosis factor-related apoptosis-inducing ligand receptor-1 and -2 J. Biol. Chem. 276 2001 3270 3278
36. P. Clarke, S. Meintzer, S. Gibson, C. Widmann, T. Garrington, G. Johnson, and K. Tyler Reovirus-induced apoptosis is mediated by TRAIL J. Virol. 74 2000 8135 8139
37. B. Mundt, F. Kuhnel, L. Zender, Y. Paul, H. Tillmann, C. Trautwein, M.P. Manns, and S. Kubicka Involvement of TRAIL and its receptors in viral hepatitis FASEB J. 17 2003 94 96
38. J. Bischoff, D. Kirn, A. Williams, C. Heise, S. Horn, M. Muna, L. Ng, J. Nye, A. Sampson-Johannes, A. Fattaey, and F. McCormick An adenovirus mutant that replicates selectively in p53-deficient human tumor cells Science 274 1996 373 376
39. C. Heise, A. Sampson-Johannes, A. Williams, F. McCormick, D.D. Vonhoff, and D.H. Krin ONYX015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents Nat. Med. 3 1997 639 645
40. C. Carla, C. Heise, A.M. Williams, S. Xue, M. Propst, and D.H. Kirn Intravenous administration of ONYX015, a selectively replicating adenovirus, induces antitumor efficacy Cancer Res. 59 1999 2623 2628
41. K.R. Rogulski, S.O. Freytag, K. Zhang, J.D. Gilbert, D.L. Paielli, J.H. Kim, C.C. Heise, and D.H. Kirn In Vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy Cancer Res. 60 2000 1193 1196
42. J. Nemunaitis, I. Ganly, F. Khuri, J. Arseneau, J. Kuhn, T. McCarty, S. Landers, P. Maples, L. Romel, B. Randlev, T. Reid, S. Kaye, and D. Kirn Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial Cancer Res. 60 2000 6359 6366
43. D. Kirn, R.L. Martuza, and J. Zwiebel Replication-selective virotherapy for cancer: biological principles, risk management and future directions Nat. Med. 7 2001 781 787
44. S. Qiu, H. Ruan, Z. Pei, B. Hu, P. Lan, J. Wang, Z. Zhang, J. Gu, L. Sun, C. Qian, X. Liu, and Y. Qi Combination of gene-virotherapy (Zd55-hTRAIL) and chemotherapy (5-FU) enhances antitumor and oncolytic efficacy in malignant colorectal carcinoma cancer J. Interferon Cytokine Res. 24 2004 219 230
45. D.J. Kenyon, J. Dougherty, and J.K. Raska Tumorigenicity of adenovirus transformed cells and their sensitivity to tumor necrosis factor and NK/LAK cell cytolysis Virology 180 1991 818 821
46. K.T. Goldsmith, L.D. Dion, D.T. Curiel, and R.I. Garver Trans E1 component requirements for maximal replication of E1-defective recombinant adenovirus Virology 406 1998 406 419
47. S.W. Lowe, H.E. Ruley, T. Jacks, and D.E. Housman p53-dependent apoptosis modulates the cytotoxicity of anticancer agents Cell 74 1993 957 967
48. T.A. Walker, B.A. Wilson, A.M. Lewis Jr., and J.L. Cook E1A oncogene induction of cytolytic susceptibility eliminates sarcoma cell tumorigenicity Proc. Natl. Acad. Sci. USA 88 1991 6491 6495
49. J.L. Cook, D.N. Ikle, and B.A. Routes Natural killer cell ontogeny in the athymic rat: relationship between functional maturation and acquired resistance to E1A oncogene-expressing sarcoma cells J. Immunol. 155 1995 5512 5518